Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.

Ernani V, Jahan R, Smith LM, Marr AS, Kimbrough SE, Kos ME, Tijerina J, Pivovar S, Lakshmanan I, Ketcham M, Rauth S, Mallya K, Nasser MW, Jain M, Kessinger A, Batra SK, Ganti AK.

Cancer Treat Res Commun. 2019 Oct 7;22:100162. doi: 10.1016/j.ctarc.2019.100162. [Epub ahead of print]

2.

Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells.

Mirzapoiazova T, Li H, Nathan A, Srivstava S, Nasser MW, Lennon F, Armstrong B, Mambetsariev I, Chu PG, Achuthan S, Batra SK, Kulkarni P, Salgia R.

J Clin Med. 2019 Oct 18;8(10). pii: E1723. doi: 10.3390/jcm8101723.

3.

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.

Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R.

J Clin Med. 2019 Jul 16;8(7). pii: E1038. doi: 10.3390/jcm8071038.

4.

Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.

Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, Salgia R.

Cancer Biol Ther. 2018;19(11):1023-1032. doi: 10.1080/15384047.2018.1472193. Epub 2018 Oct 12.

5.

Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.

Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST, Ghoshal K.

J Biol Chem. 2018 Aug 17;293(33):12945. doi: 10.1074/jbc.W118.004967. No abstract available.

6.

Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation.

Ahirwar DK, Nasser MW, Ouseph MM, Elbaz M, Cuitiño MC, Kladney RD, Varikuti S, Kaul K, Satoskar AR, Ramaswamy B, Zhang X, Ostrowski MC, Leone G, Ganju RK.

Oncogene. 2018 Aug;37(32):4428-4442. doi: 10.1038/s41388-018-0263-7. Epub 2018 May 3.

PMID:
29720724
7.

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.

Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R.

Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.

8.

Emerging trends in the immunotherapy of pancreatic cancer.

Banerjee K, Kumar S, Ross KA, Gautam S, Poelaert B, Nasser MW, Aithal A, Bhatia R, Wannemuehler MJ, Narasimhan B, Solheim JC, Batra SK, Jain M.

Cancer Lett. 2018 Mar 28;417:35-46. doi: 10.1016/j.canlet.2017.12.012. Epub 2017 Dec 12. Review.

9.

STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade.

Varikuti S, Oghumu S, Elbaz M, Volpedo G, Ahirwar DK, Alarcon PC, Sperling RH, Moretti E, Pioso MS, Kimble J, Nasser MW, Ganju RK, Terrazas C, Satoskar AR.

Oncoimmunology. 2017 Aug 14;6(11):e1361088. doi: 10.1080/2162402X.2017.1361088. eCollection 2017.

10.

MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.

Gautam SK, Kumar S, Cannon A, Hall B, Bhatia R, Nasser MW, Mahapatra S, Batra SK, Jain M.

Expert Opin Ther Targets. 2017 Jul;21(7):657-669. doi: 10.1080/14728222.2017.1323880. Epub 2017 May 29. Review.

11.

TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer.

Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser MW, Shilo K, Ganju RK.

Oncotarget. 2016 May 27;9(71):33459-33470. doi: 10.18632/oncotarget.9663. eCollection 2018 Sep 11.

12.

Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.

Elbaz M, Ahirwar D, Ravi J, Nasser MW, Ganju RK.

Oncotarget. 2017 May 2;8(18):29668-29678. doi: 10.18632/oncotarget.9408.

13.

RAGE: A novel target for breast cancer growth and metastasis.

Nasser MW, Ahirwar DK, Ganju RK.

Oncoscience. 2016 Mar 3;3(2):52-3. eCollection 2016. No abstract available.

14.

Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.

Zhao H, Ahirwar DK, Oghumu S, Wilkie T, Powell CA, Nasser MW, Satoskar AR, Li DY, Ganju RK.

Mol Oncol. 2016 Feb;10(2):272-81. doi: 10.1016/j.molonc.2015.10.007. Epub 2015 Oct 28.

15.

Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway.

Ravi J, Elbaz M, Wani NA, Nasser MW, Ganju RK.

Mol Carcinog. 2016 Dec;55(12):2063-2076. doi: 10.1002/mc.22451. Epub 2016 Jan 6.

PMID:
26741322
16.

Erratum to: miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer.

Zhao H, Wilkie T, Deol Y, Sneh A, Ganju A, Basree M, Nasser MW, Ganju RK.

Mol Cancer. 2015 Nov 16;14(1):195. doi: 10.1186/s12943-015-0451-9. No abstract available.

17.

Non-contact method for directing electrotaxis.

Ahirwar DK, Nasser MW, Jones TH, Sequin EK, West JD, Henthorne TL, Javor J, Kaushik AM, Ganju RK, Subramaniam VV.

Sci Rep. 2015 Jun 9;5:11005. doi: 10.1038/srep11005.

18.

Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.

Nasser MW, Elbaz M, Ahirwar DK, Ganju RK.

Cancer Lett. 2015 Aug 28;365(1):11-22. doi: 10.1016/j.canlet.2015.05.002. Epub 2015 May 8. Review.

PMID:
25963887
19.

Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.

Powell CA, Nasser MW, Zhao H, Wochna JC, Zhang X, Shapiro C, Shilo K, Ganju RK.

Oncotarget. 2015 Mar 20;6(8):6373-85.

20.

Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.

Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE 3rd, Ganju RK.

Mol Oncol. 2015 Apr;9(4):906-19. doi: 10.1016/j.molonc.2014.12.010. Epub 2015 Jan 19.

21.

miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer.

Zhao H, Wilkie T, Deol Y, Sneh A, Ganju A, Basree M, Nasser MW, Ganju RK.

Mol Cancer. 2015 Jan 27;14:11. doi: 10.1186/s12943-014-0275-z. Erratum in: Mol Cancer. 2015;14(1):195.

22.

RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment.

Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K, Ostrowski M, Shapiro C, Carson WE 3rd, Ganju RK.

Cancer Res. 2015 Mar 15;75(6):974-85. doi: 10.1158/0008-5472.CAN-14-2161. Epub 2015 Jan 8.

23.

C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.

Wani N, Nasser MW, Ahirwar DK, Zhao H, Miao Z, Shilo K, Ganju RK.

Breast Cancer Res. 2014 May 29;16(3):R54. doi: 10.1186/bcr3665.

24.
25.

CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model.

Oghumu S, Varikuti S, Terrazas C, Kotov D, Nasser MW, Powell CA, Ganju RK, Satoskar AR.

Immunology. 2014 Sep;143(1):109-19. doi: 10.1111/imm.12293.

26.

Evaluation of banana hypersensitivity among a group of atopic egyptian children: relation to parental/self reports.

El-Sayed ZA, El-Ghoneimy DH, El-Shennawy D, Nasser MW.

Allergy Asthma Immunol Res. 2013 May;5(3):150-4. doi: 10.4168/aair.2013.5.3.150. Epub 2013 Feb 4.

27.

Differential role of psoriasin (S100A7) in estrogen receptor α positive and negative breast cancer cells occur through actin remodeling.

Sneh A, Deol YS, Ganju A, Shilo K, Rosol TJ, Nasser MW, Ganju RK.

Breast Cancer Res Treat. 2013 Apr;138(3):727-39. doi: 10.1007/s10549-013-2491-4. Epub 2013 Mar 28.

28.

S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways.

Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X, Leone G, Wolf R, Yuspa SH, Ganju RK.

Cancer Res. 2012 Feb 1;72(3):604-15. doi: 10.1158/0008-5472.CAN-11-0669. Epub 2011 Dec 12.

29.

Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.

Deol YS, Nasser MW, Yu L, Zou X, Ganju RK.

J Biol Chem. 2011 Dec 30;286(52):44845-54. doi: 10.1074/jbc.M111.225466. Epub 2011 Oct 20.

30.

Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion.

Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, Ganju RK.

PLoS One. 2011;6(9):e23901. doi: 10.1371/journal.pone.0023901. Epub 2011 Sep 7.

31.

Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis.

Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE, Ganju RK.

Cancer Prev Res (Phila). 2011 Jan;4(1):65-75. doi: 10.1158/1940-6207.CAPR-10-0181. Epub 2010 Nov 19.

32.

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK.

Mol Cancer Ther. 2009 Nov;8(11):3117-29. doi: 10.1158/1535-7163.MCT-09-0448. Epub 2009 Nov 3.

33.

MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.

Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K.

J Biol Chem. 2009 Nov 13;284(46):32015-27. doi: 10.1074/jbc.M109.016774. Epub 2009 Sep 2.

34.

Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.

Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM.

J Immunol. 2009 Sep 1;183(5):3425-32. doi: 10.4049/jimmunol.0900305. Epub 2009 Aug 10.

35.

Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.

Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST, Ghoshal K.

J Biol Chem. 2008 Nov 28;283(48):33394-405. doi: 10.1074/jbc.M804788200. Epub 2008 Sep 25. Retraction in: J Biol Chem. 2018 Aug 17;293(33):12945.

36.

Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis.

Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K, Jacob ST.

Cancer Res. 2008 Jul 1;68(13):5049-58. doi: 10.1158/0008-5472.CAN-07-6655.

37.

Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer.

Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM.

J Immunol. 2008 Apr 15;180(8):5699-706.

38.

CXCR1 and CXCR2 activation and regulation. Role of aspartate 199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor internalization.

Nasser MW, Raghuwanshi SK, Malloy KM, Gangavarapu P, Shim JY, Rajarathnam K, Richardson RM.

J Biol Chem. 2007 Mar 2;282(9):6906-15. Epub 2007 Jan 4.

39.
40.

Cross-desensitization among CXCR1, CXCR2, and CCR5: role of protein kinase C-epsilon.

Nasser MW, Marjoram RJ, Brown SL, Richardson RM.

J Immunol. 2005 Jun 1;174(11):6927-33.

Supplemental Content

Loading ...
Support Center